China Universal Asset Management Co. Ltd. Has $26,000 Stock Holdings in Lyell Immunopharma, Inc. $LYEL

China Universal Asset Management Co. Ltd. cut its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 94.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 2,966 shares of the company’s stock after selling 55,637 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Lyell Immunopharma were worth $26,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in Lyell Immunopharma during the 1st quarter worth approximately $345,000. Almitas Capital LLC increased its position in Lyell Immunopharma by 136.3% during the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after buying an additional 1,432,086 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma in the second quarter valued at about $258,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on LYEL. HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their target price for the stock from $20.00 to $45.00 in a report on Tuesday, December 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Monday, September 1st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $45.00.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $32.40 on Tuesday. The business has a fifty day moving average price of $20.23 and a two-hundred day moving average price of $14.33. The stock has a market capitalization of $688.18 million, a PE ratio of -1.41 and a beta of -0.11. Lyell Immunopharma, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $35.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. As a group, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.